Peter J. Chen

Peter J. Chen

Auto-generated profile, based on publicly available information

Peter J. Chen

Merkin Institute of Transformative Technologies in Healthcare, Broad Institute of Harvard and MIT, Cambridge, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2019 in Nature
Verified
Journal Article
Closed access
PDF file
AAAndrew V. Anzalone
Andrew V. Anzalone
PRPeyton B. Randolph
Peyton B. Randolph
JDJessie R. Davis
Jessie R. Davis
ASAlexander A. Sousa
Alexander A. Sousa
LKLuke W. Koblan
Luke W. Koblan
DLDavid R. Liu
David R. Liu

1 October 2021 in Cell
Verified
Journal Article
Open access
PCPeter J. Chen
Peter J. Chen
JHJeffrey A. Hussmann
Jeffrey A. Hussmann
JYJun Yan
Jun Yan
FKFriederike Knipping
Friederike Knipping
PRPurnima Ravisankar
Purnima Ravisankar
DLDavid R. Liu
David R. Liu
While prime editing enables precise sequence changes in DNA, cellular determinants of prime editing remain poorly understood. Using pooled CRISPRi screens, we discovered that DNA mismatch repair (MMR) impedes prime editing and promotes undesired indel byproducts. We developed PE4 and PE5 prime editing systems in which transient expression of an engineered MMR-inhibiting protein enhances the efficiency of substitution, small insertion, and small deletion prime edits by an average 7.7-fold and 2.0-fold compared to PE2 and PE3 systems, respectively, while improving edit/indel ratios by 3.4-fold in MMR-proficient cell types. Strategic installation of silent mutations near the intended edit can enhance prime editing outcomes by evading MMR. Prime editor protein optimization resulted in a PEmax architecture that enhances editing efficacy by 2.8-fold on average in HeLa cells. These findings enrich our understanding of prime editing and establish prime editing systems that show substantial improvement across 191 edits in seven mammalian cell types.

4 October 2021 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
JNJames W. Nelson
James W. Nelson
PRPeyton B. Randolph
Peyton B. Randolph
SSSimon P. Shen
Simon P. Shen
KEKelcee A. Everette
Kelcee A. Everette
PCPeter J. Chen
Peter J. Chen
DLDavid R. Liu
David R. Liu

7 November 2022 in Nature Reviews Genetics
Verified
Journal Article
Closed access
PDF file
PCPeter J. Chen
Peter J. Chen
DLDavid R. Liu
David R. Liu

4 May 2023 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
JDJessie R. Davis
Jessie R. Davis
SBSamagya Banskota
Samagya Banskota
JLJonathan M. Levy
Jonathan M. Levy
GNGregory Newby
Gregory Newby
XWXiao Wang
Xiao Wang
DLDavid R. Liu
David R. Liu
Realizing the promise of prime editing for the study and treatment of genetic disorders requires efficient methods for delivering prime editors (PEs) in vivo. Here we describe the identification of bottlenecks limiting adeno-associated virus (AAV)-mediated prime editing in vivo and the development of AAV-PE vectors with increased PE expression, prime editing guide RNA stability and modulation of DNA repair. The resulting dual-AAV systems, v1em and v3em PE-AAV, enable therapeutically relevant prime editing in mouse brain (up to 42% efficiency in cortex), liver (up to 46%) and heart (up to 11%). We apply these systems to install putative protective mutations in vivo for Alzheimer’s disease in astrocytes and for coronary artery disease in hepatocytes. In vivo prime editing with v3em PE-AAV caused no detectable off-target effects or significant changes in liver enzymes or histology. Optimized PE-AAV systems support the highest unenriched levels of in vivo prime editing reported to date, facilitating the study and potential treatment of diseases with a genetic component.

17 February 2023 in Blood
Verified
Journal Article
Open access
PDF file
CLChang Li
Chang Li
AGAphrodite Georgakopoulou
Aphrodite Georgakopoulou
GNGregory A Newby
Gregory A Newby
PCPeter J. Chen
Peter J. Chen
KEKelcee A Everette
Kelcee A Everette
ALAndré Lieber
André Lieber
Sickle Cell Disease (SCD) is a monogenic disease caused by a nucleotide mutation in the β-globin gene. Current gene therapy studies are mainly focused on lentivirus vector-mediated gene addition or CRISPR/Cas9-mediated fetal globin reactivation, leaving the root cause unfixed. We developed a vectorized prime editing system that can directly repair the SCD mutation in hematopoietic stem cells (HSCs) in vivo in a SCD mouse model (CD46/Townes mice). Our approach involved a single intravenous injection of a non-integrating, prime editor-expressing virus vector into mobilized CD46/Townes mice and low-dose drug selection in vivo. This procedure resulted in the correction of ~40% of bS alleles in HSCs. On average 43% of HbS was replaced by HbA thereby greatly mitigating the SCD phenotypes. Transplantation in secondary recipients demonstrated that long-term repopulating HSCs were edited. Highly efficient target site editing was achieved with minimal generation of insertions and deletions and no detectable off-target editing. Because of its simplicity and portability, our in vivo prime editing approach has the potential for application in resource-poor countries where SCD is prevalent.